HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: IND Applications For Cosmetic Trials? Lauder Appointment; P&G At Olympics

This article was originally published in The Rose Sheet

Executive Summary

Comments may be submitted through April 7 regarding cosmetics-related sections in an FDA guidance that could impose the costs and burden of Investigational New Drug application on beauty companies conducting clinical trials. More news in brief.

You may also be interested in...



Unilever Looks To Personal-Care Innovation, Improved “Agility” In FY 2014

Unilever reports a 3% decline in FY 2013 turnover, but underlying sales growth was ahead of market, the firm says, crediting strong innovation in personal care and successes in emerging markets, among other factors. Going forward the firm aims to create efficiencies via SKU reductions and other streamlining efforts.

FDA Guidance Could Impose Drug-Like Burden On Cosmetic Trials

An FDA guidance document intended to clarify if firms conducting certain drug studies involving human subjects are obligated to file Investigational New Drug Applications instead raises questions for the cosmetics industry.

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019350

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel